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Introduction
Endoscopic mucosal resection (EMR) is a safe and effective
treatment for large (≥20mm) colorectal polyps [1, 2], with
low procedural morbidity and mortality when compared to sur-
gery [3–5]. Lesion size, location, extent, histology, endoscopist
expertise, and adherence to post-polypectomy surveillance
may limit success of EMR [6–11]. Polyps on the ileocecal valve
(ICV) pose challenges for EMR because extension into and
around the valve orifice and into terminal ileum create difficulty
in accessing lesions and is associated with a relatively high risk
for recurrence [6, 12, 13]. We analyzed the success of EMR of
large ICV lesions, post-polypectomy complications and recur-
rence rate compared to the non- ICV polyps. To our knowledge,
this is the largest series to specifically address the endoscopic
resection of ICV lesions.
Patients and methods
This is a retrospective review of a prospectively maintained da-
tabase of large colorectal polyps that were resected by a single
experienced endoscopist (D.K.R) since 2000 at an academic
university hospital. Permission to review the de-identified data-
base was granted by the Indiana University Health Institutional
Review board on September 29, 2015. All sessile polyps and flat
lesions located at the ICV and ≥20mm in size and referred for
EMR were included, with referred non-ICV polyps ≥20mm as a
control group. ICV polyps were considered to be lesions that
extended onto one or more lips of the ICV orifice. The database
includes age, gender, shape, size (as measured by endoscopist
estimate with an open snare of known diameter as the refer-
ence), location in the colon, endoscopic methods of resection
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ABSTRACT
Background and study aims Ileocecal valve (ICV) lesions
are challenging to remove endoscopically.
Patients and methods This was a retrospective cohort
study, performed at an academic tertiary US hospital. Ses-
sile polyps or flat ICV lesions ≥20mm in size referred for
endoscopic mucosal resection (EMR) were included. Suc-
cessful resection rates, complication rates and recurrence
were compared to lesions ≥20mm in size not located on
the ICV.
Results During an 18-year interval, there were 118 ICV le-
sions ≥20mm with mean size 28.6mm (44.9% females;
mean age 71.6 years), comprising 9.03% of all referred
polyps. Ninety ICV lesions (76.3%) were resected endo-
scopically, compared to 91.3% of non-ICV lesions (P <
0.001). However, in the most recent 8 years, successful
EMR of ICV lesions increased to 93%. Conventional adeno-
mas comprised 92.2% of ICV lesions and 7.8% were serrated.
Delayed hemorrhage and perforation occurred in 3.3% and
0% of ICV lesions, respectively, compared to 4.8% and 0.5%
in the non-ICV group. At first follow-up, rates of residual
polyp in the ICV and non-ICV groups were 16.5% and
13.6%, respectively (P=0.485). At second follow-up residual
rates in the ICV and non-ICV lesion groups were 18.6% and
6.7%, respectively (P= .005).
Conclusions Large ICV polyps are a common source of ter-
tiary referrals. Over an 18-year experience, risk of EMR for
ICV polyps was numerically lower, and risk of recurrence
was numerically higher at first follow and significantly higher
at second follow-up compared to non-ICV polyps.
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including any closure that was performed, histology, complica-
tions and the results of follow-up examinations.
EMRs in the study were performed in 2000 through 2017.
Polyp size was measured using a snare of known size. Lesions
with a maximum diameter along the colon wall < 20mm in size
(more than a third of all referred lesions) were excluded from
the study and data on their resection is not included here.
Lesions were referred for surgery if they had overt evidence
of cancer on endoscopic inspection, if portions of the lesions
were deemed inaccessible (this perception clearly evolved over
the study interval), if polyp features of bulk or fibrosis (some-
times in combination with access issues) prevented resection,
or if a resected lesion showed invasive cancer on pathology.
EMRs were performed using high-definition colonoscopes as
they became available and a distal attachment on the colono-
scope tip (Olympus distal attachment, Olympus Corp, Center
Valley, Pennsylvania, United States) was utilized after it became
available. The cap was placed so that it extended 3 to 4mm be-
yond the colonoscope tip. EMR technique included submucosal
injection with saline or 10% dextrose injection or with hydro-
xyethyl starch in later years. In all cases indigo carmine or me-
thylene blue was added to the injectate. In most cases, injection
was started on the lesion edge closest to the ICV orifice to move
lesion away from the valve orifice and improve its accessibility.
The entire lesion was resected if possible in a single session dur-
ing the first colonoscopy. No colonoscopies were performed at
our center to “plan” an endoscopic resection. Polyps were re-
sected by piecemeal technique using low-power coagulation
current until approximately 2013, and after that using ERBE
(Elektromedizin GmbH, Germany) Endocut. If flat residual
polyp could not be snared using standard snaring techniques it
was ablated with argon plasma coagulation in the early years
and later resected using the “snare-cap” technique [14] or avul-
sion with hot biopsy forceps [15]. Hemostatic clips were ap-
plied to the EMR defect after they became available (2006)
when the size of the defect and the angle of approach allowed.
Delayed post-resection bleeding was defined as bleeding
that occurred after departure from the endoscopy unit and re-
quired return to the hospital and either transfusion, hospitaliza-
tion or repeat colonoscopy. Patients were contacted at least 30
days after EMR by telephone to identify complications.
The first surveillance colonoscopy was scheduled 4 to 6
months after EMR and the second surveillance colonoscopy
was 1 year after the first. Most patients were asked to return
to our center for follow-up but some who traveled long distan-
ces had follow-up by the referring endoscopist and their follow-
up examinations are not included. At the first and second sur-
veillance visits, the EMR site was inspected in white light as
well as narrow band imaging (NBI) and near focus if available
on the instruments (depending on the time period). Cold biop-
sy specimens of normal-appearing EMR scars without visible re-
sidual polyps were obtained on most patients at the first follow-
up throughout the study period [16]. If visible polyp was seen at
follow-up, it was resected with a snare and submitted to histo-
pathology and the edges of the polypectomy defect were abla-
ted with argon plasma coagulation (APC). After treatment, the
mucosal defect from snaring was often closed with hemoclips.
A recurrence was counted if either subjective assessment of the
site included residual polyp (whether or not confirmed by pa-
thology) or biopsies of the scar showed residual polyp. If the
site demonstrated no visible recurrence endoscopically and no
biopsies were obtained of the resection site, we considered
there was no recurrence at that surveillance examination. Can-
cer was defined as submucosal invasion of dysplasia.
For purposes of comparing trends over time, we arbitrarily
divided the study period into before and after 2010. Chi-square
tests were used to compare rates of resection, residual polyp at
follow-up, bleeding, and other endpoints between the study
and control groups. Two-sample t-tests were used to compare
ages and polyp sizes between the groups.
Results
There were 1307 lateral spreading lesions ≥20mm in size, of
which 118 lesions in 118 individuals were ICV lesions (▶Table
1). Patients with ICV polyps included 53 females (44.9%) with
mean age 71.6 years (range 52–90) and 65 males (55.1%)
with mean age 67.3 years (range 41–87). Patients with ICV
polyps were older than patients with non-ICV polyps (▶Table
1). Mean polyp size was 28.7mm (range 20–70mm) and medi-
an size was 30mm (▶Table1). ICV polyps were significantly
smaller than non-ICV polyps (▶Table1).
Following endoscopic assessment, 18 ICV lesions were re-
ferred for surgical resection (▶Table 1). The most common rea-
son was lesion extension into the ileum (the lesion was still visi-
ble when the TI was actually intubated). One lesion had endo-
scopic evidence of cancer which was confirmed by endoscopic
biopsy. Conservative management (no resection and observa-
tion if appropriate) was recommended for 10 individuals be-
cause of advanced age and comorbidities. The fraction of pa-
tients recommended to have conservative therapy for ICV
polyps was higher than for non-ICV polyps (P<0.001).
Ninety ICV polyps underwent EMR and were sent to histopa-
thology. Pathology revealed tubular adenoma (n=37), tubulo-
villous adenoma (n=42), villous adenoma (n=4), hyperplastic
(n =2), and sessile serrated polyp (n =5). Excluding the 10 pa-
tients who had treatment deferred because of age and comor-
bidities, the rate of endoscopic resection prior to 2010 was 64%
(21 of 33 cases). For ICV polyps referred in 2010 and after the
rate of endoscopic resection was 92% (69 of 75 cases; P<
0.001). Sixty-four post EMR sites on the ICV (71%) had hemo-
static clips placed for prevention of delayed bleeding, com-
pared to 63% of sites not involving the ICV. Three subjects
with ICV polyps had delayed post-polypectomy hemorrhage
and were managed endoscopically. There were no perforations
in the ICV group and 5 (0.5%) in the non-ICV group.
Seventy-nine individuals with ICV lesions underwent first
surveillance colonoscopy at our center (mean interval 7.7
months, range 2.3–75 months). There was no difference be-
tween the groups with or without first follow-up surveillance
at our center (gender, P=0.11; age, P=0.94; polyp size, P=
0.46).There were 13 patients with recurrent polyp (10 with visi-
ble residual polyp verified by pathology and 3 with visible polyp
not verified by pathology), for a recurrence rate at first follow-
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up of 16.5%. Twelve of 71 ICV adenomas (16.9%) had residual
disease at first follow-up and one of eight (12.5%) non-adeno-
matous polyps had residual disease. One patient was sent for
surgical rescue based on a recurrence identified at first follow-
up. In the control group of non-ICV polyps 881 patients under-
went first follow-up at our center. There were 120 sites with re-
sidual polyp at first follow-up, including 89 with a visible recur-
rence verified by pathology, 19 with a visible recurrence not
verified by pathology, and 12 with no visible recurrence but po-
sitive biopsies for residual polyp. The overall rate of residual
polyp at first follow-up in the non-ICV polyps was 13.6% and
not different from the ICV polyps (P=0.485) (▶Table2). To
our knowledge, none of the patients treated for recurrence at
the first or second follow-up had complications from treat-
ment.
Forty-three individuals with ICV lesions completed a second
surveillance colonoscopy at our center (mean interval after first
follow up 15.7 months, range 4–60 months after the first fol-
low-up). There were five post-polypectomy sites with visible
residual polyp confirmed by histology, and three sites with visi-
ble residual polyp not verified by pathology. The recurrence
rate at the second follow-up for ICV polyps was 18.6%, includ-
ing 18.4% for 38 adenomas with second follow-up.One patient
with residual ICV polyp at the second follow-up was sent for
surgical rescue. There were 506 patients who had non-ICV
polyps who underwent a second surveillance colonoscopy at
our center. Of them, 34 had residual polyp, including 25 with
visible polyp verified by pathology, six that had visible polyp
not verified by pathology, and three who had normal appearing
scars but biopsies that showed residual polyp. The rate of resi-
dual polyp at second follow-up in the non-ICV polyps was 6.7%,
which was lower than the rate at second follow-up in the ICV
polyps (P=0.005) (▶Table 2).
Discussion
To our knowledge, this series of 118 large ICV polyps is the lar-
gest series to specifically address the issue of ICV polyp resec-
tion by EMR. We found that ICV polyps represented nearly 9%
of all large polyps referred for EMR at our center. This high per-
centage of ICV lesions likely reflects the challenges of ap-
proaching lesions that are technically difficult to access be-
cause of the shape of the ICV and its orifice and the challenge
▶ Table 2 Post-polypectomy biopsy results at first and second surveil-
lance visits.
Post-polypectomy site
biopsy
ICV group Control
group
P value
1st surveillance visit 79 881
Residual polyp(s)/posi-
tive scar biopsy
13 (16.5%) 120 (13.6%) 0.485
Polypectomy scar not
biopsied
5 130
2nd surveillance visit 43 504
Residual/recurrent
polyp(s)
8 (18.6%) 34 (6.7%) 0.005
Polypectomy scar not
biopsied
10 186
ICV, ileocecal valve
▶ Table 1 Comparison of lesions located on the ileocecal valve (ICV)
and away from the valve (non-ICV).
Individuals
with ICV
polyps
(≥20mm)
Individuals
with non-ICV
polyps
(≥20mm)
P value
Total patients 118 1033
Total polyps 118 1188
Male 65 (55.1) 539 (52.2) 0.549
Female 53 (44.9) 494 (47.8)
Age (mean) at initial
procedure
69.3 65.7 < 0.001
Min age at initial
procedure
41 24
Max age at initial
procedure
90 90
Polyp size
▪ Mean size of polyp
(mm)
28.7 32.0 0.008
▪ Median size of
polyp (mm)
30 30
▪ Min size of polyp
(mm)
20 20
▪ Max size of polyp
(mm)
70 150
Polyp histology n= 118 n=1188 0.153
Tubular adenoma 44 (37.3) 469 (39.5)
Tubulovillous adeno-
ma
53 (44.9) 428 (36.0)
Villous 4 (3.4) 32 (2.7)
Hyperplastic 5 (4.2) 32 (2.7)
Sessile serrated
adenoma
7 (5.9) 163 (13.7)
Carcinoma 1 (0.8) 25 (2.1)
No biopsy taken or
available
4 (3.4) 39 (3.3)
Polyps referred to
surgery
18 (15.3) 97 (8.2) < 0.001
Conservative mana-
gement
10 (8.5) 6 (0.5) < 0.001
EMR completed 90 (76.3) 1085 (91.3) < 0.001
ICV, ileocecal valve; EMR, endoscopic mucosal resection
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of exposing lesions that extend proximally from the ICV orifice
toward the medial wall of the cecum or extend laterally into the
valley between the ICV and the lateral cecal wall. Consistent
with this suggestion, ICV lesions were significantly smaller in
size than non-ICV lesions. The resectability rate of large ICV
polyps was lower than non-ICV polyps in our experience, but in-
creased to comparable rates in the last 8 years. This likely re-
flects increased experience with EMR in general and use of tools
such as the colonoscope distal attachment to expose polyp in
the valve orifice and extending from the valve onto the medial
wall of the cecum. Further, although the rate of resectability
was lower for ICV polyps for the entire time period, absolute
rates of successful EMR were still high. Given the lower cost
and risk of EMR compared to surgical therapy [3, 17–19], EMR
is a viable option for resection of ICV polyps.
In our experience, keys to effective resection of ICV polyps
include: (1) use of a high-definition colonoscope; (2) use of a
cap on the distal end of the scope; (3) inclusion of a contrast
agent in the injection fluid; and (4) initiating injection at the
margin of the polyp with the valve orifice (▶Fig. 1, ▶Video 1).
High-definition imaging is critical to differentiate polyp tissue
from villi and small bowel mucosa, which often has a tubular
pattern near the transition between small bowel and colonic
mucosa. The short cap on the end of the colonoscope permits
the distal lip of the ICV to be tipped down, exposing the ICV or-
ifice and all surfaces of the lips of the ICV to en face examina-
tion and therapy (▶Fig. 1a) [20]. When polyp extends from
the proximal lip onto the medial wall of the cecum, the cap
▶ Fig. 1 Resection of a flat (Paris 2a) lateral spreading tumor extending around 60% of the valve circumference. There is considerable fecal
material in the cecum. a The valve is turned en face to the colonoscope tip by the pressure of the cap on the valve lip at the bottom of the photo.
There is fecal debris in the cap on the left. Yellow arrows designate the edge of the lesion closest to the valve orifice. Red arrows designate the
visible edge of the lesion that is furthest from the orifice. b The yellow line outlines the ileal orifice. At the lower right the needle is ready for
insertion along the polyp edges nearest the orifice, in order to push the lesion away from the orifice. c The yellow line encircles a polyp edge on
the distal lip of the valve on the margin with ileal mucosa that is enclosed in a polypectomy snare. The blue arrow points to small bowel villi that
are enclosed in the snare. The green arrows point to as yet unresected polyp on the proximal lip of the valve. d,e Resection continues on the
proximal edge. Note how the cap forces the distal lip of the valve down, exposing polyp on the proximal lip for resection.
Video 1 A flat polyp on the right edge of the valve. Note the
injection is performed on the aspect of the lesion closest to the
valve orifice. The cap is used to force the distal lip of the valve
down and turn the lesion on face. The cap is also used at some
points to enable snaring and resection [14]. Submucosal fat is ex-
posed in some areas, a common occurrence in ascending colon
lesions and a consistent occurrence in valve lesions.
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can be used to force the entire valve down, exposing the muco-
sa between the ICV and the appendiceal orifice to examination
and treatment (▶Video 1). Inclusion of a contrast agent in the
injectate also helps to differentiate the polyp margin from small
bowel mucosa, which as noted can be challenging in the transi-
tion zone between small bowel and colonic mucosa. Finally, in-
itiating injection at the lesion margin adjacent to the valve ori-
fice can push the polyp away from the orifice, improving expo-
sure of the polyp (▶Fig. 1b, ▶Video 1). Some caution is need-
ed in applying this rule to lesions on the proximal lip of the ori-
fice, because injection at the lesion edge on the orifice may
push the lesion away from the colonoscope tip into the valley
between the ICV and appendiceal orifice. The endoscopist
must anticipate the effects of injection, and control the injec-
tion volume so that it improves rather than impedes exposure
of the lesion.
We found that recurrence rates for polyps on the ICV were
similar to non-ICV polyps at first follow-up, but higher at sec-
ond follow-up compared to non-ICV polyps. Some may ques-
tion our definition of residual polyp, because it included lesions
where the endoscopist identified residual polyp but the pathol-
ogist was unable to verify this when the residual polyp was re-
sected. In the ICV group, only 43 patients underwent a second
examination at our center, and three of eight recurrences were
not verified by pathology. The rationale for using this definition
is that areas of residual polyp at follow-up are often tiny (just a
few millimeters in diameter) and often very flat. We routinely
employed low-power coagulation current with a snare to resect
areas of residual polyp. This approach was designed to deliver
enough coagulation effect to destroy residual polyp tissue that
was typically located on a scar. Thus, the treatment could be
reasonably expected to sometimes thermally destroy the resi-
dual polyp tissue in the attempt at resection, and our anecdotal
impression is that this was often the case. Given this, this defi-
nition of recurrence may be the most appropriate definition of
recurrence. However, we acknowledge that if recurrence defini-
tion is confined to lesions with histologically documented resi-
dual polyp, we would not have found a higher recurrence rate at
second follow-up.Our data suggest that lesions involving the
ICV orifice should undergo two follow-ups.
A previous study of 53 large ICV lesions had results mostly
similar to ours [12]. Thus, EMR was achieved in 93.6% and
81.1% ultimately avoided surgery. The recurrence rate at first
follow-up was 17.5%, the delayed bleeding rate was 6.4%, and
there were no perforations. Unlike in our study, the recurrence
rate at the second follow-up was only one in 22 (4.5%). Thus,
the previous study did not show an unexpectedly high rate of
recurrence at follow-up.
Strengths of our study include its large size, and that we pro-
spectively accumulated the data. Our methods for collecting
cases make us confident that all referred sessile and flat lesions
≥20mm in size were included. We expect the main observa-
tions here to have good generalizability. Limitations of the
study include the retrospective design and incomplete follow-
up of all lesions at our center. Also, although the total number
of ICV lesions is larger than any previously reported study spe-
cifically addressing this issue, the total number of lesions that
had two follow-ups is small. With regard to patients “lost” to
follow-up, our center is a referral center for EMR for patients
within and outside of Indiana. Lower rates of follow-up should
not be perceived as a weakness of EMR based on our study, be-
cause many patients had planned follow-up elsewhere due to
distance from our center and are not included in follow-up re-
sults reported here. We consider the number of follow-ups at
our center sufficiently large to make observations about recur-
rence rates likely to be accurate. In addition, the span of the
study is long, and improved imaging over the study interval
and improved techniques might mean that the overall rate of
recurrence for the study period overestimates the rates that
would be expected with expert EMR technique applied with
current colonoscopes and other EMR tools.
Conclusion
In summary, the high number of referred lesions on the ICV in-
dicates the technical challenges of EMR at this location. In a
large experience of EMR, resectability of large ICV lesions was
numerically lower than non-ICV lesions, but increased with
time and endoscopist experience. In recent years, endoscopic
resectability rates of ICV and non-ICV polyps were equivalent,
indicating that large non-pedunculated ICV lesions are resect-
able at rates comparable to non-ICV lesions, and should gener-
ally be endoscopically resected or referred for endoscopic re-
section by experts and should not be referred for surgical resec-
tion based on location alone. Complication rates were numeri-
cally lower for ICV polyps compared to non-ICV polyps. Recur-
rence rates were numerically higher for ICV compared to non-
ICV polyps at first follow-up, and significantly higher at second
follow-up.Overall, EMR is an effective and safe approach to re-
section of large ICV polyps.
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